08-20-2015, 03:04 AM
(This post was last modified: 08-20-2015, 03:05 AM by SunilNagpal.)
Intarcia Therapeutics Inc. has emerged with an implantable drug-delivery pump which is suggested to have been proved superior to currently existent Merck's Januvia drug.
Sized of a matchstick, this pump called ITCA 650, comes loaded with a whole year of supply of commonly used diabetes drug Exenatide.
The results have come post a year-long study involving 535 patients with Type 2 diabetes. Intarcia expects to publish the trial results in a journal and exhibit in medical meetings.
Sized of a matchstick, this pump called ITCA 650, comes loaded with a whole year of supply of commonly used diabetes drug Exenatide.
Quote:ITCA 650 is implanted in abdominal tissue and can release the medicine continuously in minute quantities ensuring a steady state of medicine availability in the body and keeping the blood sugar levels in check.
The results have come post a year-long study involving 535 patients with Type 2 diabetes. Intarcia expects to publish the trial results in a journal and exhibit in medical meetings.
![[+]](https://www.biotechnologyforums.com/images/netpen-pro/collapse_collapsed.png)